Anzeige
Erschienen in:
01.04.2017 | Erratum
Erratum to: The Efficacy and Safety of Tolvaptan in Patients with Hyponatremia: A Meta-Analysis of Randomized Controlled Trials
Erschienen in: Clinical Drug Investigation | Ausgabe 4/2017
Einloggen, um Zugang zu erhaltenExcerpt
In the original publication, Figs. 3, 4, 5 and 6 were labelled incorrectly. Below are the correct versions of Figs. 3, 4, 5 and 6:
Fig. 3
Effect of tolvaptan on changes in serum sodium concentrations (a) and serum sodium correction rates (b) in patients with hyponatremia. CI confidence interval, df degrees of freedom, IV inverse variance, M–H Mantel–Haenszel, SD standard deviation
Fig. 4
Effect of tolvaptan on 24-h urine output (a) and net fluid balance (b) in patients with hyponatremia. CI confidence interval, df degrees of freedom, IV inverse variance, SD standard deviation
Fig. 5
Impact of tolvaptan on adverse event rates (a) and serious adverse event rates (b) in patients with hyponatremia. CI confidence interval, df degrees of freedom, M–H Mantel–Haenszel
Fig. 6
Impact of tolvaptan on changes in systolic blood pressure (a) and changes in heart rate (b) in patients with hyponatremia. CI confidence interval, df degrees of freedom, IV inverse variance, SD standard deviation
× ![]()
× ![]()
× ![]()
× ![]()
…